A detailed history of Pro Share Advisors LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 15,321 shares of MGNX stock, worth $49,946. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,321
Previous 12,018 27.48%
Holding current value
$49,946
Previous $51,000 1.96%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.0 - $5.55 $9,909 - $18,331
3,303 Added 27.48%
15,321 $50,000
Q2 2024

Aug 13, 2024

SELL
$3.31 - $18.51 $10,803 - $60,416
-3,264 Reduced 21.36%
12,018 $51,000
Q1 2024

May 08, 2024

BUY
$9.77 - $21.47 $12,173 - $26,751
1,246 Added 8.88%
15,282 $224,000
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $9,322 - $21,038
2,081 Added 17.41%
14,036 $135,000
Q3 2023

Nov 13, 2023

BUY
$4.48 - $6.19 $170 - $235
38 Added 0.32%
11,955 $55,000
Q2 2023

Aug 10, 2023

BUY
$4.62 - $7.54 $2,591 - $4,229
561 Added 4.94%
11,917 $63,000
Q1 2023

May 11, 2023

SELL
$4.82 - $7.24 $7,157 - $10,751
-1,485 Reduced 11.56%
11,356 $81,000
Q4 2022

Feb 02, 2023

BUY
$3.34 - $6.98 $3,426 - $7,161
1,026 Added 8.68%
12,841 $86,000
Q3 2022

Nov 04, 2022

BUY
$3.01 - $5.22 $800 - $1,388
266 Added 2.3%
11,815 $41,000
Q2 2022

Aug 01, 2022

SELL
$2.25 - $9.99 $13,623 - $60,489
-6,055 Reduced 34.4%
11,549 $34,000
Q1 2022

May 10, 2022

SELL
$8.12 - $16.9 $33,405 - $69,526
-4,114 Reduced 18.94%
17,604 $156,000
Q4 2021

Feb 08, 2022

BUY
$15.91 - $21.88 $15,464 - $21,267
972 Added 4.69%
21,718 $348,000
Q3 2021

Nov 12, 2021

SELL
$19.74 - $28.7 $105,510 - $153,401
-5,345 Reduced 20.49%
20,746 $434,000
Q2 2021

Aug 13, 2021

BUY
$20.49 - $35.63 $74,768 - $130,013
3,649 Added 16.26%
26,091 $701,000
Q1 2021

May 14, 2021

BUY
$18.99 - $33.2 $30,744 - $53,750
1,619 Added 7.78%
22,442 $715,000
Q4 2020

Feb 09, 2021

BUY
$19.41 - $26.0 $109,258 - $146,354
5,629 Added 37.05%
20,823 $476,000
Q3 2020

Nov 13, 2020

BUY
$24.69 - $31.6 $20,813 - $26,638
843 Added 5.87%
15,194 $383,000
Q2 2020

Aug 03, 2020

BUY
$5.2 - $29.12 $74,625 - $417,901
14,351 New
14,351 $401,000
Q1 2020

May 15, 2020

SELL
$4.28 - $12.11 $72,926 - $206,342
-17,039 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$7.95 - $12.27 $12,926 - $19,951
-1,626 Reduced 8.71%
17,039 $185,000
Q3 2019

Nov 12, 2019

BUY
$12.44 - $17.48 $3,396 - $4,772
273 Added 1.48%
18,665 $238,000
Q2 2019

Aug 13, 2019

SELL
$14.51 - $19.71 $35,447 - $48,151
-2,443 Reduced 11.73%
18,392 $312,000
Q1 2019

May 15, 2019

BUY
$11.11 - $25.6 $26,441 - $60,928
2,380 Added 12.9%
20,835 $375,000
Q4 2018

Feb 14, 2019

SELL
$11.75 - $21.42 $41,865 - $76,319
-3,563 Reduced 16.18%
18,455 $234,000
Q3 2018

Nov 14, 2018

SELL
$19.26 - $23.46 $16,968 - $20,668
-881 Reduced 3.85%
22,018 $472,000
Q2 2018

Aug 13, 2018

BUY
$19.78 - $24.67 $29,571 - $36,881
1,495 Added 6.98%
22,899 $473,000
Q1 2018

May 14, 2018

SELL
$18.89 - $32.46 $65,472 - $112,506
-3,466 Reduced 13.94%
21,404 $539,000
Q4 2017

Feb 14, 2018

BUY
$16.19 - $20.3 $29,368 - $36,824
1,814 Added 7.87%
24,870 $473,000
Q3 2017

Nov 13, 2017

BUY
$15.52 - $18.94 $33,290 - $40,626
2,145 Added 10.26%
23,056 $426,000
Q2 2017

Aug 11, 2017

BUY
N/A
20,911
20,911 $366,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.